<DOC>
	<DOCNO>NCT00677313</DOCNO>
	<brief_summary>This open-label study provide metreleptin treatment diabetes mellitus and/or hypertriglyceridemia associate lipodystrophy . This study intend provide guidance investigator respect identification appropriate subject metreleptin treatment , guidance metreleptin dosing , collection safety efficacy data follow metreleptin treatment population</brief_summary>
	<brief_title>An Open-Label Treatment Protocol Provide Metreleptin Treatment Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>Is male female ≥5 year old If female childbearing potential ( include perimenopausal woman menstrual period within one year ) : 1 . Not breastfeed 2 . Negative pregnancy test result 3 . Must practice willing continue practice appropriate birth control ( define method result low failure rate , i.e. , less 1 % per year , use consistently correctly , implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire duration study ( Double barrier method include use female diaphragm male condom spermicide also use . ) Has physicianconfirmed lipodystrophy define evidence generalize ( whole body ) partial ( limbs ) loss body fat outside range normal variation Has diagnose least one follow 2 metabolic disorder : 1 . Diabetes Mellitus 2 . Hypertriglyceridemia define fast triglyceride concentration &gt; 200 mg/dL If ≥18 year age , able read , understand , sign Informed Consent Form ( ICF ) Authorization Use Disclose Protected Health Information form , communicate investigator , understand comply protocol requirement If &lt; 18 year age , parent legal guardian read understand ICF Child Assent Form , communicate investigator , understand comply protocol requirement . Adolescent subject must also read understand Child Assent Form ; child young unable read , Child Assent Form must explain child . Has diagnose HIV infection Has know infectious liver disease Has know allergy E. coliderived protein hypersensitivity component study treatment</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>metreleptin</keyword>
	<keyword>leptin</keyword>
	<keyword>Amylin</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>lipodystrophy</keyword>
</DOC>